Skip to main content

Semax vs ARA-290

Both Semax and ARA-290 are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.

Semax

Evidence B

Semax (MEHFPGP)

A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.

View full Semax profile →

ARA-290

Evidence B

ARA-290 (Cibinetide)

An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.

View full ARA-290 profile →

Side-by-Side

AttributeSemaxARA-290
Evidence GradeBB
FDA StatusNot FDA-approved in US — approved in Russia for stroke and cognitive disordersNot FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy
Typical Dose200–600 mcg intranasal, morningTrial range: 1–4 mg subcutaneous daily
Clinics Indexed899
Categoriescognitive, neuroprotectionanti-inflammatory, neuroprotection

Key reported benefits — Semax

  • BDNF increase
  • Enhanced focus
  • Memory improvement
  • Neuroprotection

Key reported benefits — ARA-290

  • Small-fiber neuropathy improvement
  • Anti-inflammatory
  • No erythrocytosis

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons